10x Genomics, Inc. Form 8-K Summary
Business context and reporting period
10x Genomics filed a Current Report on Form 8-K regarding a November 20, 2019 ruling by the Munich Regional Court in litigation brought by Bio-Rad Laboratories, Inc. The report was signed on November 25, 2019. The filing concerns the Company’s Chromium instruments, GEM microfluidic chips, and related accessories sold or imported into Germany.
Financial and operating information
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other periodic financial metrics.
- The Court ordered 10x Genomics to bear statutory legal-dispute costs of at least €61,000.
- Bio-Rad is entitled to unspecified damages; the filing does not provide a quantified liability or estimate of the potential total cost.
Material changes and legal developments
- The Court ruled that certain GEM microfluidic chips, Chromium instruments, and accessories used with GEM systems infringe German Utility Model No. DE 20 2011 110 979.
- The Court issued an injunction prohibiting, among other activities, the sale and importation of the affected products in Germany.
- The Court required the affected products to be recalled from German distribution channels.
- The remedies, including the injunction, become effective upon enforcement after Bio-Rad posts a bond.
- The German Utility Model expires on November 1, 2021.
- The ruling did not address Next GEM products, which were not accused in the action and represented the majority of the Company’s sales in Germany, according to the filing.
Outlook, risks, contingencies, and unusual items
10x Genomics previously filed an action on September 5, 2018, seeking cancellation of the German Utility Model before the German Patent and Trademark Office. No hearing had been scheduled as of the filing date.
Key risks include potential disruption of sales and imports of affected products in Germany, product recall obligations, unspecified damages, legal costs, and possible operational or commercial effects if the injunction is enforced. The filing does not state whether the Company has recorded an accrual or quantify the potential financial impact.
Important facts to verify
- Whether Bio-Rad has posted the required bond and whether the injunction has been enforced.
- The amount of damages ultimately claimed or awarded and any related accounting accrual.
- The scope and cost of the required recall in Germany.
- The status and outcome of 10x Genomics’ cancellation action against the German Utility Model.
- The effect of the ruling on German sales, distribution, customer use, and availability of affected Chromium and GEM products.